Does LANADELUMAB Cause Product dose omission issue? 555 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 555 reports of Product dose omission issue have been filed in association with LANADELUMAB (TAKHZYRO). This represents 27.0% of all adverse event reports for LANADELUMAB.
555
Reports of Product dose omission issue with LANADELUMAB
27.0%
of all LANADELUMAB reports
15
Deaths
307
Hospitalizations
How Dangerous Is Product dose omission issue From LANADELUMAB?
Of the 555 reports, 15 (2.7%) resulted in death, 307 (55.3%) required hospitalization, and 12 (2.2%) were considered life-threatening.
Is Product dose omission issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LANADELUMAB. However, 555 reports have been filed with the FAERS database.
What Other Side Effects Does LANADELUMAB Cause?
Hereditary angioedema (1,343)
Weight decreased (361)
Weight increased (353)
Inappropriate schedule of product administration (318)
Product use issue (229)
Covid-19 (225)
Injection site pain (201)
Insurance issue (172)
Drug ineffective (142)
Stress (137)
What Other Drugs Cause Product dose omission issue?
DUPILUMAB (18,189)
USTEKINUMAB (9,405)
GUSELKUMAB (9,267)
LENALIDOMIDE (8,145)
MEPOLIZUMAB (5,873)
TOFACITINIB (5,646)
VOXELOTOR (5,122)
BELIMUMAB (4,671)
SECUKINUMAB (4,572)
APREMILAST (4,460)
Which LANADELUMAB Alternatives Have Lower Product dose omission issue Risk?
LANADELUMAB vs LANADELUMAB-FLYO
LANADELUMAB vs LANREOTIDE
LANADELUMAB vs LANSOPRAZOLE
LANADELUMAB vs LANTHANUM
LANADELUMAB vs LANTUS